Uploaded May 2026 | Updated September 2026, 1 week ago
The pace of change in cardiometabolic medicine is accelerating. University Hospitals, Ian Neeland, MD, breaks down the latest innovations in incretin therapies, from oral medications to cuting-edge combinations, and what they mean for weight loss, heart health and long-term patient care.
Disclaimer: Dr. Neeland is a consultant for Boehringer Ingelheim, Eli Lilly, and Bayer.
The Science@UH Podcast (the Podcast) is intended for informational and educational purposes only. It should not be used as a replacement for medical advice. The statements about devices, drugs, software, or other products may not have been reviewed by the Food and Drug Administration (FDA). The effectiveness of these products may not have been verified by FDA-approved studies. These products are not designed to diagnose, treat, cure, or prevent any disease. University Hospitals (UH) or a guest on the Podcast may have ownership of licensed intellectual property of this research study. As such, UH or a guest could receive financial gain from the outcomes of this research.
The pace of change in cardiometabolic medicine is accelerating. University Hospitals, Ian Neeland, MD, breaks down the latest innovations in incretin therapies, from oral medications to cuting-edge combinations, and what they mean for weight loss, heart health and long-term patient care.
Disclaimer: Dr. Neeland is a consultant for Boehringer Ingelheim, Eli Lilly, and Bayer.
The Science@UH Podcast (the Podcast) is intended for informational and educational purposes only. It should not be used as a replacement for medical advice. The statements about devices, drugs, software, or other products may not have been reviewed by the Food and Drug Administration (FDA). The effectiveness of these products may not have been verified by FDA-approved studies. These products are not designed to diagnose, treat, cure, or prevent any disease. University Hospitals (UH) or a guest on the Podcast may have ownership of licensed intellectual property of this research study. As such, UH or a guest could receive financial gain from the outcomes of this research.
